# Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients

> **NCT06657859** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Glycomine, Inc.** · enrollment: 90 (estimated)

## Conditions studied

- Pmm2-CDG
- Phosphomannomutase 2 Deficiency

## Interventions

- **DRUG:** GLM101

## Key facts

- **NCT ID:** NCT06657859
- **Lead sponsor:** Glycomine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-09-30
- **Primary completion:** 2029-09
- **Final completion:** 2029-10
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06657859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06657859, "Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06657859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*